Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BMP1 | P13497 | 2/20 | 0.38 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.35 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.35 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.35 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.35 |
| ▸ | ECE1 | P42892 | 3/20 | 0.32 |
| ▸ | TASP1 | Q9H6P5 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29591087 | 0.83 | ECE1 (0.46) | BMP1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL30382233 | 0.83 | BMP1 (0.44) | BMP1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL27422192 | 0.83 | GRIN2D (0.45) | BMP1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL29380522 | 0.82 | ECE1 (0.43) | BMP1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL26429408 | 0.81 | ALOX15 (0.35) | BMP1 | |
| SCHEMBL26429181 | 0.81 | ALOX15 (0.35) | BMP1 | |
| SCHEMBL29140277 | 0.80 | ALOX15 (0.34) | — | |
| SCHEMBL29630368 | 0.79 | GLO1 (0.44) | BMP1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL31722878 | 0.79 | FOLH1 (0.46) | BMP1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL30544309 | 0.78 | ECE1 (0.49) | BMP1GRIN2DGRIN3BGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230127524-A1 | FILAMENTOUS NANOSTRUCTURES AND THEIR USE FOR TREATMENT OF PULMONARY DISEASE | NATIONAL SCIENCE FOUNDATION | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230127524-A1 | FILAMENTOUS NANOSTRUCTURES AND THEIR USE FOR TREATMENT OF PULMONARY DISEASE | MFAP1, DIAPH1, SEPTIN7 | BMP1 1279/4885GRIN2D 4510/4885GRIN3B 4509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.